The Broad Implications of The SAUL Study

The Broad Implications of The SAUL Study

Annual-Meeting

5 months
208 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dr. Cora Sternberg Of Weill Cornell Medicine and NewYork-Presbyterian discusses the broader implications of the SAUL study. Background: Atezo, a monoclonal antibody targeting PD-L1, is an approved therapy for locally advanced/metastatic UC based on IMvigor210 and IMvigor211 phase II and III trials. The single-arm SAUL study (NCT02928406) with a broader patient (pt) population demonstrated median overall survival (OS) of 8.7 months and a safety profile consistent with previous atezo trials. Methods: Pts with locally advanced/metastatic UC or non-UC of the urinary tract received atezo 1200 mg every 3 weeks until disease progression or unacceptable toxicity. Populations excluded from IMvigor211 (renal impairment, ECOG PS 2, treated asymptomatic CNS metastases, stable controlled autoimmune disease, concomitant steroids, HIV positive, non-UC) were eligible. The primary endpoint was safety; OS and overall response rate (ORR) were secondary endpoints. Predefined subgroup analyses included outcomes according to PD-L1 status (VENTANA SP142) and age in the overall population (and the IMvigor211-like subgroup for PD-L1). Results: Between Nov 2016 and Mar 2018, 1004 pts were enrolled; 997 received atezo. Efficacy is summarized below. Incidences of grade ?3 treatment-related adverse events were similar irrespective of PD-L1 status (overall IC 0/1 vs 2/3: 11% vs 16%; IMvigor211-like IC 0/1 vs 2/3: 11% vs 15%) or age (?65 y: 13%; ?75 y: 12%; ?80 y: 10%). Conclusions: OS and ORR appear more favorable in IC 2/3 vs IC 0/1 subgroups (overall and in the IMvigor211-like population). Atezo was effective and well tolerated across subgroups including elderly pts. Clinical trial information: NCT02928406
Up Next Autoplay
EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
Category: Bladder Cancer
13 Views
Cancer-News 1 month
EV-103 Phase I Trial Presented at #ESMO19
EV-103 Phase I Trial Presented at #ESMO19
Category: Bladder Cancer
21 Views
Cancer-News 1 month
Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Category: Bladder Cancer
30 Views
Cancer-News 2 months
Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer
Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer
Category: Bladder Cancer
22 Views
Cancer-News 2 months
Strategies for Treating 2nd Line RCC Patients
Strategies for Treating 2nd Line RCC Patients
Category: Bladder Cancer
54 Views
obr 4 months
Treating Newly Diagnosed RCC Patients
Treating Newly Diagnosed RCC Patients
Category: Bladder Cancer
53 Views
obr 4 months
Data on Enfortumab in Post-Platinum and I-O Bladder Cancer
Data on Enfortumab in Post-Platinum and I-O Bladder Cancer
Category: Bladder Cancer
110 Views
obr 4 months
Combo Ipilimumab + Nivolumab in Histologies of Bladder Cancer
Combo Ipilimumab + Nivolumab in Histologies of Bladder Cancer
Category: Bladder Cancer
49 Views
obr 4 months
TROPHY-u-01 Trial: A Phase II Open-Label Study Of Sacituzumab Govitecan (IMMU-132) In Patients With Advanced Urothelial Cancer
TROPHY-u-01 Trial: A Phase II Open-Label Study Of Sacituzumab Govitecan (IMMU-132) In Patients With Advanced Urothelial Cancer
Category: Bladder Cancer
175 Views
Annual-Meeting 5 months